Tempus AI and AstraZeneca announced a foundational model partnership.
4 reports, 2 independent
Updated Aug 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tempus AI and AstraZeneca announced a foundational model partnership.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Tempus
biotechnology company based in Chicago, Illinois
-
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Geopolitical instability in the Middle East has led to significant corporate fallout, including the cancellation of Flutter's London Stock Exchange listing and AstraZeneca considering a move to the US market.
Related events
Coverage
Newest first; wire copies grouped- ZacksTempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy? Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company’s adjuste
- Insider MonkeyTempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) m
- ZacksTempus AI Raises 2025 Financial Outlook: What's Backing It? Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximatel
- Unknown outlet